Taurus Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Taurus Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,193	Closed	-$206K	–	106
2017 Q2	$206K	Buy	+6,193	New	+$192K	0.03%	93
2017 Q1	–	Sell	-6,893	Closed	-$250K	–	95
2016 Q4	$250K	Buy	6,893 +200	+3%	+$7.99K	0.05%	84
2016 Q3	$308K	Buy	6,693 +500	+8%	+$26.1K	0.06%	77
2016 Q2	$311K	Hold	6,193	–	–	0.05%	78
2016 Q1	$331K	Hold	6,193	–	–	0.06%	76
2015 Q4	$407K	Hold	6,193	–	–	0.08%	71
2015 Q3	$350K	Sell	6,193 -2,900	-32%	-$188K	0.07%	77
2015 Q2	$537K	Hold	9,093	–	–	0.1%	73
2015 Q1	$566K	Sell	9,093 -60	-0.7%	-$3.49K	0.11%	73
2014 Q4	$526K	Hold	9,153	–	–	0.09%	76
2014 Q3	$492K	Hold	9,153	–	–	0.1%	76
2014 Q2	$480K	Hold	9,153	–	–	0.09%	77
2014 Q1	$484K	Hold	9,153	–	–	0.1%	81
2013 Q4	$367K	Hold	9,153	–	–	0.08%	89
2013 Q3	$346K	Hold	9,153	–	–	0.08%	86
2013 Q2	$359K	Buy	+9,153	New	+$356K	0.09%	87

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Taurus Asset Management's TEVA Position: Q3 2017 in Review

Taurus Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 6,193 shares — an estimated $206K sold.

Taurus Asset Management first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $566K in Q1 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Taurus Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Taurus Asset Management sold 6,193 Teva Pharmaceuticals shares in Q3 2017, an estimated $206K.
Taurus Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Taurus Asset Management's Teva Pharmaceuticals position peaked at $566K in Q1 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Taurus Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.